Health Catalyst (HCAT) Projected to Post Quarterly Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Health Catalyst to post earnings of $0.11 per share and revenue of $79.59 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $5.01 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 1 year low of $4.96 and a 1 year high of $9.24. The firm has a market capitalization of $304.85 million, a PE ratio of -3.71 and a beta of 1.34. The business’s 50 day moving average price is $6.19 and its 200-day moving average price is $7.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 21st. Citigroup dropped their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Stephens increased their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Royal Bank of Canada lowered their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Finally, Wells Fargo & Company cut their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $10.20.

Insider Activity at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the sale, the insider now owns 236,950 shares in the company, valued at $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the completion of the transaction, the general counsel now directly owns 72,250 shares in the company, valued at approximately $601,120. This trade represents a 21.05 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 87,610 shares of company stock worth $664,043. Insiders own 2.50% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.